Tolochenaz, Vaud, Switzerland — Nanolive SA, a leading live cell imaging and analysis company, announces today that it has successfully completed the initial closing of US $20 million in the Series C-1 equity financing round of investment, led by a US-based and NASDAQ listed life science investor, and Taiwania Capital, the leading life science venture capital company based in Taiwan. This equity round of investment is also supported by investments from existing investors, including Swisscom Ventures, along with other partners. Nanolive is working closely with investors to secure a second close within ninety days.

Nanolive’s cutting edge label-free microscope devices and state-of-the-art digital analytical solutions provide researchers and scientists working in the biopharmaceutical industry and laboratories with all the tools required to accelerate innovation in growth industries such as drug discovery and cell therapy.

Being able to screen thousands of living cells in 3D, without damaging them promises to radically advance how scientists study living cells. But the quantitative analytical suite Nanolive offers is a complete game-changer. Combining sub-cellular resolution with unique AI-assisted digital assays provide researchers and scientists a unique opportunity to study complex cell-drug perturbation dynamics and cell-cell interactions (e.g., T cell and target cell interactions), quantitatively, an approach that will revolutionize the cell-based assay phase of the drug discovery workflow.

“Life Sciences are undergoing a fundamental transformation, and Nanolive is at the heart of it,” says Dr. Yann Cotte, Nanolive’s CEO and Co-Founder. “We are honored to receive an investment from such an impressive group of investors who are excited to support us in our goal to transform the discovery and development of therapeutics. With this fundraising, we believe Nanolive is well positioned to drive significant growth of our Digital Assay solutions and is at the leading edge of this global bioeconomy gold rush. We are selling the best picks and shovels for live cell solutions.”

“We are thrilled to be part of a Swiss-based innovative company that will revolutionize the drug discovery process,” said Michael L. Huang, Managing Partner of Taiwania Capital. “With this funding, Nanolive is well positioned to provide crucial tools and solutions to pharmaceutical and biotech companies, and research institutes for developing better therapies that would save millions of patient lives”.

ABOUT NANOLIVE SA

Nanolive SA is a Swiss company pioneer in the development and commercialization of innovative label-free, non-invasive live cell imaging and state-of-the-art digital analytical solutions. Nanolive’s breakthrough live cell imaging and analysis platforms accelerate innovation in growth industries such as drug discovery and cell therapy. The Swiss company’s groundbreaking solutions combine screening, imaging, and analysis to radically advance how scientists study living cells and provide novel biological insights such as the mechanisms of cancer and neurodegenerative diseases.

Find more information on www.nanolive.ch and follow the company on LinkedIn.

ABOUT TAIWANIA CAPITAL

Taiwania Capital is a leading venture capital company in Taiwan focusing on investing in early to late-stage firms with a mission to build partnerships between Taiwan and worldwide partners by leveraging expertise of Taiwan’s world-class ICT industry, vibrant biotech ecosystems, and exceptional healthcare services. With funds designated for life science and bio-converging technologies, Taiwania focuses on breakthrough technologies in therapeutics, medical technology, and healthcare.